Stored Tissue Samples from People With Extramedullary Multiple Myeloma
Checks whether archived tissue from adults with spreading myeloma can support biomarker research.
Plain-language title generated from the registry record
Registry title: Multiple Myeloma Extramedulary Disease Samples FFPE
Key facts
- Where
- Lyon 06, FranceSee the site
Where in France
- BIWAKOLyon 06, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BIWAKO
- Trial code
- NCT07354555
- Record updated
- 20 March 2026
- Original description
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.Read full original descriptionShow less
Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma Extramedulary Disease
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.
No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.
Inclusion: Adult patients with histologically confirmed extramedullary myeloma (excluding plasmacytoma); Availability of a representative FFPE block from a surgical specimen; Diagnosis established within the past 10 years; Availability of associated clinical and follow-up data.
Exclusion: Patients with plasmacytoma only; Insufficient or non-representative FFPE material; Missing key diagnostic or clinical data.